Roche News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

05.02.19	Roche submits supplemental biologics license application to US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment (GlobeNewswire)
01.02.19	CHMP recommends EU approval of Roche's Hemlibra for people with severe haemophilia A without factor VIII inhibitors (GlobeNewswire)
01.02.19	CHMP recommends EU approval of Roche's Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer (GlobeNewswire)
31.01.19	Roche mit sehr gutem Jahresergebnis für 2018 (GlobeNewswire)
31.01.19	Roche reports very strong results in 2018 (GlobeNewswire)
30.01.19	Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer's disease (AD) - other company programmes in AD continue (GlobeNewswire)
17.12.18	PRIME designation granted by European Medicines Agency for Roche's risdiplam for treatment of spinal muscular atrophy (SMA) (GlobeNewswire)
10.12.18	Neues Mitglied zur Wahl in den Verwaltungsrat von Roche vorgeschlagen (GlobeNewswire)
10.12.18	New member proposed for election to Roche Board of Directors (GlobeNewswire)
10.12.18	Änderungen in der Konzernleitung von Roche (GlobeNewswire)
10.12.18	Changes to the Roche Corporate Executive Committee (GlobeNewswire)
07.12.18	FDA approves Roche's Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer (GlobeNewswire)
05.12.18	Roche's Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment (GlobeNewswire)
05.12.18	FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer (GlobeNewswire)
04.12.18	New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia (GlobeNewswire)
03.12.18	Roche's Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors (GlobeNewswire)
03.12.18	Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
21.11.18	Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy (GlobeNewswire)
13.11.18	FDA grants priority review to Roche's Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer (GlobeNewswire)
01.11.18	Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting (GlobeNewswire)
01.11.18	Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities (GlobeNewswire)
01.11.18	Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia (GlobeNewswire)
29.10.18	Neue Daten der STAIRWAY-Studie zeigen mögliche längere Wirkdauer für Faricimab von Roche bei neovaskulärer altersbedingter Makuladegeneration (nAMD) (GlobeNewswire)
29.10.18	New STAIRWAY study data shows potential for extended durability with Roche's faricimab in neovascular age-related macular degeneration (nAMD) (GlobeNewswire)
24.10.18	Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza (GlobeNewswire)
22.10.18	Roche's Alecensa (alectinib) significantly reduced the risk of disease worsening or death as first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer (GlobeNewswire)
22.10.18	Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-small cell lung cancer live significantly longer compared to chemotherapy alone (GlobeNewswire)
21.10.18	Roche's investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours (GlobeNewswire)
20.10.18	Roche's Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer (GlobeNewswire)
17.10.18	Roche mit sehr gutem Wachstum in den ersten neun Monaten 2018 (GlobeNewswire)
17.10.18	Roche reports very strong growth in the first nine months of 2018 (GlobeNewswire)
15.10.18	Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research (GlobeNewswire)
15.10.18	Roche's Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment (GlobeNewswire)
10.10.18	OCREVUS (ocrelizumab) data show early initiation of treatment reduces disability progression over five years in relapsing and primary progressive multiple sclerosis (GlobeNewswire)
10.10.18	OCREVUS (Ocrelizumab) fünf-Jahresdaten zeigen, dass ein früher Therapiebeginn bei schubförmiger und primär progredienter multipler Sklerose das Fortschreiten der Erkrankung reduziert (GlobeNewswire)
09.10.18	Roche to present new positive data from its broad cancer immunotherapy programme and across a wide range of cancers at the European Society for Medical Oncology (ESMO) 2018 Congress (GlobeNewswire)
04.10.18	FDA approves Roche's Hemlibra for haemophilia A without factor VIII inhibitors (GlobeNewswire)
04.10.18	Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018 (GlobeNewswire)
03.10.18	Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress (GlobeNewswire)
02.10.18	Roche to present five-year OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive multiple sclerosis (MS) at ECTRIMS (GlobeNewswire)
25.09.18	Roche's Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer (GlobeNewswire)
24.09.18	Roche's investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer (GlobeNewswire)
24.09.18	Roche's Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer (GlobeNewswire)
24.09.18	Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid (GlobeNewswire)
18.09.18	Roche's NAVIFY decision support portfolio unlocks relevant content from clinical trial and medical publication databases (GlobeNewswire)
13.09.18	Roche zum zehnten Mal als nachhaltigstes Gesundheitsunternehmen im Dow Jones Sustainability Index ausgezeichnet (GlobeNewswire)
13.09.18	Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the tenth year running (GlobeNewswire)
06.09.18	Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC) (GlobeNewswire)
30.08.18	Positive phase III results for Roche's Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine (GlobeNewswire)
28.08.18	Änderungen in der Konzernleitung von Roche (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	4’059.00	2.92 %	K V
Logitech Intl	94.36	2.03 %	K V
Part Grp Hldg	1’422.50	1.07 %	K V
Sika	242.10	0.71 %	K V
Holcim	98.62	0.39 %	K V
Roche Hldg G	294.50	-1.11 %	K V
Kuehne+Nagel Int	209.20	-1.13 %	K V
Nestle	82.48	-1.43 %	K V
Swisscom	499.80	-2.00 %	K V
Novartis	95.37	-2.46 %	K V

mehr

14.02.25		Angespannte Stimmung in New York: Dow Jones beendet die Sitzung im Minus
14.02.25		Schwache Performance in New York: So bewegt sich der Dow Jones nachmittags
14.02.25		Freitagshandel in New York: Dow Jones liegt mittags im Minus
14.02.25		Handel in London: FTSE 100 zeigt sich letztendlich leichter
14.02.25		Verluste in Frankfurt: TecDAX zeigt sich schlussendlich leichter
14.02.25		Börse Zürich: SPI legt zum Handelsende den Rückwärtsgang ein
14.02.25		Aufschläge in Frankfurt: LUS-DAX schlussendlich mit positivem Vorzeichen
14.02.25		Handel in Europa: STOXX 50 zum Ende des Freitagshandels schwächer